Shanghai Model Organisms Center(SH:688265) Xin Lang Cai Jing·2025-10-30 12:55Core Viewpoint - Nanmo Bio is a leading supplier of genetically modified animal models in China, providing critical technical support for the biopharmaceutical industry with a full industry chain service capability [1] Group 1: Business Performance - In Q3 2025, Nanmo Bio achieved a revenue of 303 million yuan, ranking 24th among 29 companies in the industry [2] - The company's net profit for the same period was 26.76 million yuan, placing it 19th in the industry [2] - Revenue breakdown: standardized models accounted for 48.34% (94.62 million yuan), model technical services for 21.92% (42.90 million yuan), model breeding for 19.50% (38.17 million yuan), customized models for 9.34% (18.29 million yuan), and other revenue for 0.91% (1.77 million yuan) [2] Group 2: Financial Ratios - As of Q3 2025, Nanmo Bio's debt-to-asset ratio was 10.38%, down from 11.82% year-on-year and significantly lower than the industry average of 22.79%, indicating strong solvency [3] - The company's gross profit margin was 52.87%, an increase from 43.63% year-on-year and above the industry average of 37.70%, reflecting strong profitability [3] Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 2.53% to 6,687, while the average number of circulating A-shares held per shareholder decreased by 2.47% to 11,700 [5] - Tianhong Medical Health A became a new major shareholder with 377,400 shares, while Rongtong Health Industry Flexible Allocation Mixed A/B exited the top ten circulating shareholders [5] Group 4: Executive Compensation - The chairman, Fei Jian, received a salary of 500,000 yuan in 2024, an increase of 100,000 yuan from 2023 [4] - The company is controlled by Shanghai Dish Enterprises Management Consulting Co., Ltd., with Wang Mingjun and Fei Jian as the actual controllers [4]